Terazosin is an FDA-approved medicine that has been used primarily for men and data for women are missing. For the first time, the target engagement of Terazosin in neurodegenerative diseases was assessed for both sexes. We chose the βATP/Pi ratio as a biomarker to study the brain energy metabolism and found strong correlations between the in vivo brain ATP levels to whole blood ATP levels. We observed clear sex differences in response to different TZ doses in both mice and humans. Our data suggest that the optimal dose for females may need to be lower as compared to males.
How to access this content:
For one year after publication, abstracts and videos are only open to registrants of this annual meeting. Registrants should use their existing login information. Non-registrant access can be purchased via the ISMRM E-Library.
After one year, current ISMRM & ISMRT members get free access to both the abstracts and videos. Non-members and non-registrants must purchase access via the ISMRM E-Library.
After two years, the meeting proceedings (abstracts) are opened to the public and require no login information. Videos remain behind password for access by members, registrants and E-Library customers.
Keywords